Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.
PET-MPs may exacerbate IPF by inducing oxidative stress, mitochondrial damage, and inflammation in pulmonary cells, leading to chronic lung injury. The study identified AKT1, PIM1, and PIK3CD as core ...
Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback